ImmunityBio, Inc.

IBRX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$67-$93-$130-$59
Dep. & Amort.$0$4$4$4
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$10$10$9
Change in WC$0-$6-$22-$11
Other Non-Cash-$2$5$52-$28
Operating Cash Flow-$69-$80-$86-$85
Investing Activities
PP&E Inv.$0-$1-$1-$2
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$15-$0-$6
Inv. Sales/Matur.$0$0$5$18
Other Inv. Act.-$181$0$0$0
Investing Cash Flow-$181-$16$4$10
Financing Activities
Debt Repay.$0-$0$0$0
Stock Issued$0$173$0$108
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$174-$0-$1-$1
Financing Cash Flow$174$173-$1$107
Forex Effect-$0$0-$0-$0
Net Chg. in Cash-$77$77-$83$32
Supplemental Information
Beg. Cash$138$61$144$112
End Cash$61$138$61$144
Free Cash Flow-$69-$81-$87-$87
ImmunityBio, Inc. (IBRX) Financial Statements & Key Stats | AlphaPilot